Claims for Patent: 8,790,899

Summary for Patent: 8,790,899

Title:	Real-time PCR assays for rapid detection and differentiation of the Clostridium botulinum toxin genes A, B, E, and F
Abstract:	Provided herein is a method for detecting the presence or absence of at least one of Clostridium botulinum toxin gene A, B, E, and F in a biological sample by means of PCR amplification using toxin specific primers and labeled probes in connection with real time or delayed detection. Also provided are specific primer and probe sequences, a diagnostic method and a kit comprising primers and probes for detection of toxin genes A, B, E, or F in a biological sample.
Inventor(s):	Robison; Richard A. (Provo, UT), Pickett; David O. (Knoxville, TN), Satterfield; Ben (Webster, TX)
Assignee:
Application Number:	12/873,300
Patent Claims:	1. A multiplexing reaction method for detecting the presence or absence of at least one of Clostridium botulinum toxin gene A, B, E, and F in a biological sample, the method comprising: a. preparing a nucleic acid mixture comprising DNA from the biological sample; b. providing a purified polynucleic acid primer having at least 90% sequence homology to SEQ ID NO:2 and at least one isolated and purified polynucleic acid primer pair configured for use in at least one of a PCR or other amplification reaction and selected from the group consisting of sequences having at least 90% sequence homology to SEQ ID NOS: 1, 3-4, 5-6, and 7-8; c. providing at least one polynucleic acid probe selected from the group consisting of sequences having at least 90% sequence homology SEQ ID NOS 9, 10, 11, and 12, wherein each probe is labeled with a different detectable label; d. conducting an amplification reaction with a DNA polymerase using the mixture; and e. detecting hybridization of any of the at least one probe to the amplification product of step d. wherein detection is one of real time detection and delayed detection and wherein hybridization indicates the presence of at least one of toxin genes A, B, E, or F in the biological sample. 2. The method of claim 1, wherein said detectable label is a fluorescent label. 3. The method of claim 1, wherein said detectable label is selected from the group consisting of FAM, Cy3, Cy5 and Texas Red (TexR). 4. The method of claim 1, wherein a signal from at least two detectable labels is displayed simultaneously on at least two optical channels. 5. The method of claim 1, wherein the sample is from a mammal. 6. The method of claim 5, wherein the sample is selected from the group consisting of serum, secretion, emesis, wound, tissue, blood, fluid, and feces. 7. The method of claim 6, wherein the sample is from a human. 8. The method of claim 1, wherein the sample is vegetative matter. 9. The method of claim 1, wherein the sample is one of a food product or medicant suitable for ingestion by an animal. 10. The method of claim 1, wherein the sample is one of a food product or medicant suitable for ingestion by a human. 11. The method of claim 9, wherein the sample comprises a public food supply. 12. The method of claim 11, further comprising issuing a public health advisory based on a result positive for at least one of C. botulinum toxin gene A, B, E, and F. 13. The method of claim 1 further comprising diagnosing C. botulinum in a human by determining the presence or absence of at least one C. botulinum toxin gene in a sample from a human according claim 7, and correlating the presence or absence the C. botulinum toxin gene in the sample with the diagnosis of the human as being one of infected or not infected with C. botulinum. 14. The method of claim 13 further comprising administering C. botulinum anti-toxin effective against at least one toxin produced by the at least one identified C. botulinum toxin gene. 15. A composition for detecting multiple botulinum toxin groups in a multiplexing reaction, the composition comprising: a. an isolated and purified polynucleic acid primer configured to function in at least one of a PCR and other amplification reaction and having at least 90% sequence homology to GTGCTAATGYTACYGCTGGATCTG (SEQ ID NO:2) and at least one isolated and purified polynucleic acid primer configured to function in at least one of a PCR and other amplification reaction and having at least 90% sequence homology to the sequence of at least one of ACGCGAAATGGTTATGGYTCTACTC(SEQ ID NO:1), AGTAATCCAGGAGAAGTGGAGCGA (SEQ ID NO:3), CRAAGCCTTCCCTTGATGCAAA (SEQ ID NO:4), CACAGAAAGTGCCCGAAGGTGAAA (SEQ ID NO:5), GCTGCTTGCACAGGTTTATTGACA (SEQ ID NO:6), GTGGAGGGMATMATAGTAGTACAGA (SEQ ID NO:7), and GGCTATCATAAGAGGTSCTYGCTTT (SEQ ID NO:8), wherein Y represents at least one of T and C, M represents at least one of A and C, R represents at least one of A and G, and S represents at least one of C and G. 16. The composition according to claim 15, further comprising at least one polynucleic acid probe labeled with a detectable label and having at least 90% sequence homology to at least one of TGAGGAGTCACTTGAAGTTGATACAAATCC (SEQ ID NO:9), CGCAAATTTAATAATATTTGGACCTGGGCC (SEQ ID NO:10), GTCAATCTCACCTCTTCAATTGATACAGCA (SEQ ID NO:11), AGCTCATGAATTGATACATGCACTGCA (SEQ ID NO:12). 17. A kit for detecting the presence of at least one of Clostridium botulinum toxin genes A, B, E, and F in a biological sample, the kit comprising: a. an isolated and purified polynucleic acid primer configured for use in a PCR reaction and having at least 90% sequence homology to SEQ ID NO:2; b. at least one isolated and purfied polynucleic acid primer configured for use in a PCR reaction and having least 90% sequence homology to a sequence selected from the group consisting of SEQ ID NOS: 1, 3-4, 5-6, and 7-8; and c. at least one polynucleic acid probe having at least 90% sequence homology to a sequence selected from the group consisting of SEQ ID NOS: 9, 10, 11, and 12 wherein each probe is labeled with a different detectable label. 18. The kit of claim 17, further comprising instructions for performing the assay. 19. The kit of claim 18, further comprising reaction reagents. 20. The composition according to claim 15 further comprising a plurality of primers such that each possible Y nucleic acid variation for SEQ ID NO:1 is represented by at least one primer, each possible combination of Y nucleic acid variations for SEQ ID NO:2 is represented by at least one primer, each possible R nucleic acid variation for SEQ ID NO:4 is represented by at least one primer, each possible combination of M nucleic acid variations for SEQ ID NO: 7 is represented by at least one primer and each possible combination of S and Y nucleic acid variations for SEQ ID NO:8 is represented by at least one primer. 21. The composition according to claim 20 wherein within each SEQ ID NO the applicable Y, M, R, and S primer variations are present in equal molar amounts. 22. The composition according to claim 20 wherein a primer and probe for Botulinum toxin type A is present in a higher molar amount than a primer and probe for at least one of Botulinum toxin type B, E, and F. 23. The method according to claim 1 further comprising providing a plurality of primers such that each possible Y nucleic acid variation for SEQ ID NO:1 is represented by at least one primer, each possible combination of Y nucleic acid variations for SEQ ID NO:2 is represented by at least one primer, each possible R nucleic acid variation for SEQ ID NO; 4 is represented by at least one primer, each possible combination of M nucleic acid variations for SEQ ID NO: 7 is represented by at least one primer and each possible combination of S and Y nucleic acid variations for SEQ ID NO:8 is represented by at least one primer. 24. A method according to claim 23, wherein within each SEQ ID NO the applicable primers representing the Y, M, R, and S variations are provided in an equal molar amount. 25. The method according to claim 23 wherein a primer and probe for Botulinum toxin type A is provided in a higher molar amount than a primer and probe for at least one of Botulinum toxin type B, E, and F. 26. The composition of claim 16, wherein the label is a fluorescent label. 27. The composition of claim 16, wherein the label comprises at least one of FAM, Cy3, Cy5 and Texas Red (TexR).

Details for Patent 8,790,899

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2039-03-29